BioNTech Stock Dips After BNT122-01 Trial Termination
BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.
BioNTech stopped testing a cancer medicine because it wasn't working well enough. When a company pauses a medicine test, investors sometimes worry, which can make the stock price go down temporarily.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.